Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Vijay R. Nadipelli"'
Autor:
Eldon R. Jupe, Gerald H. Lushington, Mohan Purushothaman, Fabricio Pautasso, Georg Armstrong, Arif Sorathia, Jessica Crawley, Vijay R. Nadipelli, Bernard Rubin, Ryan Newhardt, Melissa E. Munroe, Brett Adelman
Publikováno v:
BioTech, Vol 12, Iss 4, p 62 (2023)
(1) Objective: Systemic lupus erythematosus (SLE) is a complex disease involving immune dysregulation, episodic flares, and poor quality of life (QOL). For a decentralized digital study of SLE patients, machine learning was used to assess patient-rep
Externí odkaz:
https://doaj.org/article/8ba90c05cea54456b978d5cd7bb61a1a
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 3, Pp n/a-n/a (2022)
Abstract Social determinants of health (SDoH) can impact the vulnerable pulmonary arterial hypertension (PAH) population, especially during the COVID‐19 pandemic. Providers' understanding of SDoH at the point of care and their impact is unknown. We
Externí odkaz:
https://doaj.org/article/7c5e4120dbdc461297e8f285a33a5ff0
Autor:
Lia N. Pizzicato, Vijay R. Nadipelli, Samuel Governor, Jianbin Mao, Stephan Lanes, John Butler, Rebecca S. Pepe, Hemant Phatak, Karim El‐Kersh
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 2, Pp n/a-n/a (2022)
Abstract Treatment for pulmonary arterial hypertension (PAH) has evolved over the past decade, including approval of new medications and growing evidence to support earlier use of combination therapy. Despite these changes, few studies have assessed
Externí odkaz:
https://doaj.org/article/ff4c5fe11f7a4316a6ec840acc62205f
Autor:
Brent, Boyett, Vijay R, Nadipelli, Caitlyn T, Solem, Howard, Chilcoat, Warren K, Bickel, Walter, Ling
Publikováno v:
Journal of Addiction Medicine. 17:182-189
This analysis describes participants' opioid use disorder (OUD) outcomes for 18 months after discontinuing extended-release buprenorphine injection (BUP-XR, SUBLOCADE).The RECOVER (Remission From Chronic Opioid Use: Studying Environmental and Socioec
Autor:
Caitlyn T. Solem, Walter Ling, Naoko A Ronquest, Vishaal Mehra, Yu-Chen Yeh, Christian Heidbreder, Vijay R Nadipelli, Susan M Learned
Publikováno v:
Journal of Substance Abuse Treatment. 110:1-8
The physical, social, psychological, and economic burden of opioid use disorder (OUD) is substantial. As of the year 2019, the predominant focus of OUD research was outcomes such as retention and abstinence. We report herein the effects of extended-r
Autor:
Walter Ling, Vishaal Mehra, Caitlyn T. Solem, Christian Heidbreder, Vijay R Nadipelli, Susan M Learned, Yu-Chen Yeh, Naoko A Ronquest
Publikováno v:
Journal of Addiction Medicine
Supplemental Digital Content is available in the text
Objective: Opioid use disorder (OUD) is associated with physical, social, psychological, and economic burden. This analysis assessed the effects of RBP-6000, referred to as BUP-XR (extended-r
Objective: Opioid use disorder (OUD) is associated with physical, social, psychological, and economic burden. This analysis assessed the effects of RBP-6000, referred to as BUP-XR (extended-r
Autor:
Namita Joshi, Maurizio Fava, Caitlyn T. Solem, Della Varghese, Susan M Learned, James A Graham, Christian Heidbreder, Vijay R Nadipelli, Rahul Dhanda
Publikováno v:
Patient Preference and Adherence. 13:1037-1050
Purpose RBP-7000 (PERSERIS™) is a once-monthly subcutaneous extended-release risperidone formulation approved by the United States Food and Drug Administration for the treatment of schizophrenia in adults. The objective of this study was to describ
Autor:
Brian Perrochet, Naoko A Ronquest, Walter Ling, Chinmay Deshpande, David Farabee, Christian Heidbreder, Vijay R Nadipelli, Susan M Learned, Caitlyn T. Solem
Publikováno v:
Substance Abuse and Rehabilitation. 10:13-21
Purpose: The Treatment Effectiveness Assessment (TEA) is a patient-centered instrument for evaluating treatment progress and recovery from substance use disorders, including opioid use disorder (OUD). We assessed the TEA's reliability and validity an
Autor:
Vishaal Mehra, James L. Andersen, Michael J. Biunno, Jelena Kunovac, Walter Ling, Barbara R. Haight, Saleem Ishaque, David R. Hassman, Gregory Seal, Scott Daniel Segal, Amanda S. Garofalo, Jesse M. Carr, Valentin Isacesu, Rakesh Ranjan, Ricky Stuart Mofsen, Otto R. Dueno, Kent Steven Hoffman, Paul J. Fudala, Brent Boyett, Shishuka Malhotra, Lawrence S. Levinson, Céline M. Laffont, Peter Paul Ventre, Eduardo Cifuentes, Sandra Daniela Duarte-Sckell, Scott Robert Bartley, Genie L. Bailey, Richard D. Knapp, Gita G. Pujari, Kyle M. Kampman, Rajinder Shiwach, Christian Heidbreder, Vijay R Nadipelli, Daniel Rutrick, Y Zhao, Rishi Kakar, Katharina Wiest, Marvin Lane Peyton, David P. Walling, Susan M Learned, Joseph A. Kwentus, Amit K. Vijapura, Haydn Mikel Thomas, Boyde J. Harrison, Mark K. Greenwald, George Konis
Publikováno v:
The Lancet. 393:778-790
RBP-6000, referred to as BUP-XR (extended-release buprenorphine), is a subcutaneously injected, monthly buprenorphine treatment for opioid use disorder. BUP-XR provides sustained buprenorphine plasma concentrations to block drug-liking of abused opio
Autor:
Arnie Aldridge, Naoko A Ronquest, Christian Heidbreder, Vijay R Nadipelli, Victoria A Albright, Susan M Learned, Vishaal Mehra, Walter Ling
Publikováno v:
Contemporary Clinical Trials. 76:93-103
Few opioid use disorder (OUD) treatment studies measure meaningful life changes during long-term recovery, focusing instead on retention and abstinence. Here, we report on the design and participant characteristics of the RECOVER study, a study explo